Holen Sie sich die Stockscreener-App
37.27
10.75%
-4.72
Schlusskurs vom Vortag:
$41.99
Offen:
$37.605
24-Stunden-Volumen:
3.68M
Relative Volume:
0.32
Marktkapitalisierung:
$14.60B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-4.2698
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
-12.37%
1M Leistung:
+9.27%
6M Leistung:
+47.15%
1J Leistung:
+21.18%
1-Tages-Spanne:
$36.66
$38.34
1-Wochen-Bereich:
$36.66
$45.50
52-Wochen-Spanne:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
37.37 | 16.41B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.40 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.67 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
823.91 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.57 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.26 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
FDA refuses to review Moderna’s mRNA flu vaccine - BioPharma Dive
The FDA declined to review Moderna’s application for the first mRNA-based flu vaccine, a decision that shocked the company and that comes as the agency plans to tighten federal vaccine approvals. https://wapo.st/4aa88Iz - facebook.com
Moderna Stock Sinks. The Puzzling Reason Its Flu Vaccine Was Rejected. - Barron's
Moderna (MRNA) Stock Falls 9% After FDA Rejects Flu Vaccine Application - Blockonomi
Moderna (MRNA) Faces Setback with FDA Refusal-to-File Letter for Influenza Vaccine - GuruFocus
First Look: Jobs Data Looms; WBD-NFLX Fight, Moderna Setback - GuruFocus
These Stocks Are Today's Movers: Moderna, Robinhood, Shopify, Kraft Heinz, Cloudflare, Humana, Lyft, Mattel, Beta Tech, and More -- Barrons.com - 富途牛牛
FDA Refuses To Review Moderna’s mRNA Flu Vaccine, Claims Trial Inadequacies - BioSpace
FDA declines to review Moderna vaccine application: "It should not be controversial" - medwatch.com
Moderna Stock Sinks. The FDA Delivers a Blow to Its New Flu Vaccine. - Barron's
First mRNA vaccine to be produced in UK approved by regulators - AOL.co.uk
FDA rejects Moderna’s application for mRNA flu shot review - Semafor
Moderna Faces FDA Setback on mRNA Flu Vaccine - TipRanks
The vaccine maker Moderna said that the FDA notified the company that the agency would not review its mRNA flu vaccine, the latest sign of federal health policy that has become hostile to vaccine development. - facebook.com
These Stocks Are Today’s Movers: Moderna, Robinhood, Cloudflare, Lyft, Mattel, Beta Technologies, Gilead, and More - Barron's
Why Is Moderna (MRNA) Stock Down Premarket? FDA Rejects Flu Vaccine Filing - Tokenist
Moderna shares drop after FDA refuses to file for mRNA-1010 influenza vaccine (MRNA:NASDAQ) - Seeking Alpha
FDA refuses to review Moderna’s mRNA flu vaccine application - AOL.com
Why Is Moderna Stock Falling Wednesday?Moderna (NASDAQ:MRNA) - Benzinga
Moderna shares fall after FDA refuses to review new flu vaccine - WKZO
Moderna (MRNA) Stock Plunges as FDA Shuts Door on Flu Vaccine Application - CoinCentral
Moderna (MRNA) Faces Setback as FDA Declines Vaccine Review - GuruFocus
Stocks to Watch Wednesday: Warner/Netflix, Moderna, SLB - The Wall Street Journal
Stocks to Watch Wednesday: Netflix, QXO, Moderna, SLB - The Wall Street Journal
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 - USA Today
Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Reduce" from Analysts - MarketBeat
FDA Tosses Flu Vaccine Application Back To Moderna With RTF Letter - Citeline News & Insights
F.D.A. Refuses to Review Moderna Flu Vaccine - The New York Times
Why Did Moderna Stock Tumble Nearly 10% After Hours Today? - Asianet Newsable
Moderna says US refusing to review mRNA-based flu shot - Caledonian Record
Moderna Says US Refusing To Review MRNA-based Flu Shot - Barron's
FDA refuses to review Moderna’s flu vaccine in latest setback - GMToday.com
Moderna Cites Changing Advice As US FDA Refuses To File Flu Vaccine BLA - Citeline News & Insights
FDA Refuses To Review Moderna's Flu Vaccine Application - Health and Me
FDA refuses to review Moderna’s application for mRNA flu vaccine, company says - KRDO
FDA Refuses to Consider Approving Use of Moderna’s New Flu Vaccine - The Wall Street Journal
Moderna (MRNA) Faces FDA Setback with Influenza Vaccine Applicat - GuruFocus
Moderna (MRNA) Shares Decline After FDA Rejects Flu Vaccine Appl - GuruFocus
FDA refuses to review Moderna's flu vaccine application - The Business Journals
Moderna shares slide 7% after FDA refuses to review flu vaccine - Investing.com
FDA Refuses to Review Moderna’s Flu Vaccine in Latest Setback - Bloomberg.com
Moderna says FDA refuses its application for new mRNA flu vaccine - Castanet
FDA refuses to review Moderna’s influenza vaccine application By Investing.com - Investing.com India
Moderna says US FDA refuses to review its influenza vaccine - TradingView
FDA refuses to review Moderna's influenza vaccine application - Reuters
Fda refuses to consider approving use of Moderna's new flu vaccineWSJ - marketscreener.com
Moderna says FDA refuses to review its application for experimental flu shot - CNBC
FDA declines to review Moderna's mRNA flu shot - NBC News
Sector Update: Health Care Stocks Mixed Late Afternoon - marketscreener.com
Moderna signs 5-year vaccine deal with Mexican government - NBC Boston
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico - USA Today
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moderna Inc-Aktie (MRNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
Dec 11 '25 |
Sale |
29.48 |
23,853 |
703,306 |
3,924 |
| Bancel Stephane | Chief Executive Officer |
Dec 11 '25 |
Option Exercise |
10.90 |
688,073 |
7,499,996 |
6,181,970 |
1.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):